JB Pharma, the fastest growing company in the Indian pharmaceutical market, marks the one-year anniversary of the launch of their identity. Good People for Good Health is a testament of the brands unwavering commitment to spreading good health globally. Crossing the milestone, the company highlights their- journey of contributions made towards Indian healthcare – of supporting healthcare providers and enriching patients’ lives globally. This is reflected in three key elements which are – their people, products, and financial results.

Sharing his views on the occasion, Mr. Nikhil Chopra, CEO & Whole-Time Director, JB Pharma said, “While we touch new horizons, we are rooted in our values of simplicity, reliability and agility that define us. We will continue to remain simple in our actions, reliable in our relationships and agile in our approach towards effecting changing scenarios in the healthcare industry.”

 Year of Consistent Outperformance:

The organisation also announced their Q4FY23 financial results. The company recorded revenue of INR 3,149 crores registering a growth of 30%. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) registered growth of 26% to Rs. 765 crores and Profit after Tax was Rs. 410 crores recording a growth of 6%. JB maintained its upward momentum with quarterly revenues at Rs. 762 crores recording a 22% increase, closing the year in excess of Rs. 3000 crores, with FY23 recording a growth of 30% to INR 3149 crores.

With a presence in 6 lakhs+ pharmacies, 40+ regulated markets, JB Pharma takes an all-encompassing approach to healthcare. Through a wide range of products and dosage forms, it has made a mark in 20+ progressive portfolios such as paediatrics, cardiology, metabolics, respiratory, anti-infectives, gastroenterology, urology, nephrology, and gynaecology. It is the fastest growing pharmaceutical company in the Indian pharma market for the 2nd consecutive financial year (IQVIA MAT Mar’23).

Robust Performance in India Business:

The domestic formulations business clocked revenue of INR 380 crores recording a growth of 29% for the quarter and was at INR 1640 crores for FY23 with a growth of 38%. Rantac, Cilacar, Cilacar-T, Metrogyl, Nicardia, Azmarda and Sporlac drove up the ranks to feature among the top 300 Indian pharmaceutical brands. JB Pharma ranks among the top 10 players in the cardiology segment and among the top 15 by prescription.

JB Pharma develops innovative products under big brands like Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl DG Gel, Nicardia XL, Sporlac EVA, Sporlac GG etc. to cater to a wide patient profile in respective therapeutic categories. With Sporlac, JB Pharma is the fastest growing among the top 3 brands in the probiotics segment in India.

Strong Progress in CDMO:

The international business performed well and grew at 16% to INR 382 crores in the quarter and 22% to INR 1509 crores for the financial year. CDMO (Contract Development & Manufacturing Organisation) business closed the year with INR 400+ crores revenue maintaining its INR 100 crores quarterly revenue run rate. In CDMO, the organisation is the 3rd largest manufacturer of herbal and medicated lozenges in the world. With 70+ products in different formats, flavours, shapes, and sizes even herbal & medicated, lozenges cater to almost 7% of the world’s total population.